Chapter 32. Potentinl Uae of Thnlidomlde in Hiviaids
- 1 January 1995
- book chapter
- Published by Elsevier
- Vol. 30, 319-327
- https://doi.org/10.1016/s0065-7743(08)60945-8
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Thalidomide and the immune system. 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primatesLife Sciences, 1994
- Tumour necrosis factor and cachexia: a current perspectiveSurgical Oncology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virusJournal of the American Academy of Dermatology, 1993
- A TH1→TH2 switch is a critical step in the etiology of HIV infectionImmunology Today, 1993
- Thalidomide in Human Immunodeficiency Virus (HIV) PatientsDrug Safety, 1992
- Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: Successful treatment with thalidomideJournal of the American Academy of Dermatology, 1990